Seer, Inc. (SEER)
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Sector: Laboratory Analytical Instruments
Industry: Biotechnology
Seer, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Not applicableCompleted
Development of a Minimally Invasive Seizure Gauge
EpiTel Epilog, Empatica E4
Epilepsy
NCT03882671Enrollment40StartJan 2019Primary CompletionDec 2023CompletionDec 2023
| Drug / Therapy | Link | ||
|---|---|---|---|
| Not applicable | Completed | EpiTel Epilog, Empatica E4 | NCT03882671 |